The Cholinesterase Inhibitors

Journal of Psychiatric Practice

Volumn 9, Issue 6, 2003, Pages 422-430

  Rubey, Robert N ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Alzheimer's dementia; Cholinesterase inhibitor; Donepezil; Galantamine; Lewy body dementia; Rivastigmine; Vascular dementia

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; ANOREXIA; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CHOLINESTERASE INHIBITION; CLINICAL TRIAL; DEMENTIA; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG CHOICE; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE COST; HEART BLOCK; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; LIVER TOXICITY; LONG TERM CARE; NAUSEA; NEUROPHARMACOLOGY; PHARMACODYNAMICS; REVIEW; SICK SINUS SYNDROME; SIDE EFFECT; TREATMENT FAILURE; VERTIGO; VOMITING;

EID: 0344736988     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200311000-00005     Document Type: Review

References (57)

1. McGeer OL, McGeer EG, Suzuki J, et al. Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain. Neurology 1984;34:741-5.
2. Zarrow C, Lyness S, Mortimer J, et al. Neuronal loss is greater in the locus caeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 2003;60:337-41.
3. Rogers J, Brogan D, Mirra S. The nucleus basalis of Meynert in neurological disease: A quantitative morphological study. Ann Neurol 1985;17:163-70.
4. Etienne P, Gauthier S, Dastoor D, et al. Alzheimer's disease: Clinical effects of lecithin treatment. New York: Raven Press; 1969:389-90.
5. Etienne P, Gauthier S, Johnson G, et al. Clinical effects of choline in Alzheimer's disease. Lancet 1978;1:508-9.
6. Watkins P, Zimmerman H, Knapp M, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-8.
7. Tiraboschi P, Hansen L, Albord M, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000;54:407-11.
8. Grantham C, Geerts H. The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease. J Neurol Sci 2002;203-204:131-6.
9. Weinstock M. Selectivity of cholinesterase inhibition. CNS Drugs 1999;12:465-80.
10. Siek G, Katz L, Fishman E, et al. Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain. Biol Psychiatry 1990;27:573-80.
11. Enz A. Cholinesterase inhibition in Alzheimer's disease: The pharmacologic basis of efficacy. In: New insights into genetics and pathophysiology of Alzheimer's disease: What are the clinical and therapeutic implications? J Clin Psychiatry 2000;61:307-15.
12. Taylor P. Development of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease. Neurology 1998;51(Suppl): S30-7.
13. Olin J, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev 2002;3:CD001717.
14. Maelicke A, Samochocki M, Jostock R, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 2001;49:279-88.
15. Nordberg A, Nilsson-Hakansson L, Adem A, et al. The role of nicotinic receptors in the pathophysiology of Alzheimer's disease. Prog Brain Res 1989;79:353-62.
16. Kennedy JS, Polinsky RJ, Johnson B, et al. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. J Clin Psychopharmacol 1999;19:513-21.
17. Polinsky RJ. Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 1998;20:634-47.
18. Spencer CM, Noble S. Rivastigmine. A review of its use in Alzheimer's disease. Drugs Aging 1998;13:391-411.
19. Ballard CG. Advances in the treatment of Alzheimer's disease: Benefits of dual cholinesterase inhibition. Eur Neurol 2002;47:64-70.
20. Farlow MR. Do cholinesterase inhibitors slow progression of Alzheimer's disease? Int J Clin Pract Suppl 2002;127:37-44.
21. Aricept (donepezil hydrochloride) package insert. Teaneck, NJ; Eisai Inc; 1998.
22. Reminyl (galantamine hydrobromide) package insert. Titusville, NJ: Janssen Pharmaceutical Products, LP; 2001.
23. Exelon (rivastigmine tartrate) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2001
24. Geldmacher D, Provenzano G, MacRae T, et al. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003;51:937-44.
25. Ward A, Caro J, Getsios D, et al. Assessment of health economics in Alzheimer's disease (AHEAD): Treatment with galantamine in the UK. Int J Geriatr Psychiatry 2003;18:740-7.
26. Folstein M, Folstein S, McHugh P. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:1889-98.
27. Rosen W, Mohs R, Davis K. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.
28. Raskind M, Peskind E, Wessel T, et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54:2261-8.
29. Farlow M, Anand R, Messina J, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000;44:236-41.
30. Doody R, Geldmacher D, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58-427-33.
31. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-95.
32. Wilkinson DG, Passmore AP, Bullock R, et al. A multinational, randomized, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 2002;56:441-6.
33. Wilcock G, Howe I, Coles H, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's Disease. Drugs Aging 2003;20:777-89.
34. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-20.
35. Parnetti L, Amici S, Lanari A, et al. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurol Sci 2002;23 (Suppl 2):S95-6.
36. Auriacombe S, Pere J, Loria-Kanza Y, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002;18:129-38.
37. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000;54:2269-76.
38. Mintzer JE, Kershaw P. The efficacy of galantamine in the treatment of Alzheimer's disease: Comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure. Int J Geriatr Psychiatry 2002 ;17:1-6.
39. Edwards K, Goodman W, Khoury K, et al. Rapid changeover from donepezil to rivastigmine is well tolerated. Poster presented at the Meeting of the American Geriatric Society, Chicago, IL, May 9-13, 2001.
40. Shua-Haim J, Smith J, Amin S. Results of switching from donepezil (Aricept) to rivastigmine (Exelon) in Alzheimer's disease patients: A two-month prospective study. Poster presented at the 7th international Geneva/Springfield Symposium on Advances in Alzheimer Therapy, Geneva, Switzerland, April 3-6, 2000.
41. Babic T, Banfic L, Papa J, et al. Spontaneous rupture of oesophagus (Boerhaave's syndrome) related to rivastigmine. Age Ageing 2000;29:370-1.
42. Taylor A, Hoehns J, Anderson D, et al. Fatal aspiration pneumonia during transition from donepezil to rivastigmine. Ann Pharmacother 2002;36:1550-3.
43. Package insert for galantamine. Physicians' desk reference. Montvale, NJ: Thompson PDR; 2003.
44. Package insert for donepezil. Physicians' desk reference. Montvale, NJ: Thompson PDR; 2003
45. Package insert for rivastigmine. Physicians' desk reference. Montvale, NJ: Thompson PDR; 2003
46. Mendez M, Younesi F, Perryman K. Use of donepezil for vascular dementia: Preliminary clinical experience. J Neuropsychiatry Clin Neurosci 1999;11:268-70.
47. Erkinjuntti T, Kurz A, Gauthier S. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial. Lancet 2002;359:1283-90.
48. Erkinjutt T, Kurz A, Small G, et al. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther 2003;25:1765-82.
49. Black S, Roman G, Geldmacher D, et al. Efficacy and tolerability of donepezil in vascular dementia. Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003;34:2331-2.
50. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-6.
51. Reisberg B, Borenstein J, Salob S, et al. Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment. J. Clin Psych 1987;48(suppl 5):9-15.
52. Samuel W, Caligiuri M, Galasko D, et al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: A preliminary study. Int J Geriatr Psychiatry 2000;15:794-802.
53. Risch S, McGurk S, Horner M, et al. A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: Functional MRI correlates. Neurocase 2001;7:105-10.
54. Friedman JI, Adler DN, Howanitz E, et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 2002;51:349-57.
55. Huxley A, Prasher V, Haque M. The dementia scale for Down's syndrome. J Intellect Disabil Res 2000;44(Pt 6):697-8.
56. Lott IT, Osann K, Doran E, et al. Down syndrome and Alzheimer disease: Response to donepezil. Arch Neurol 2002;59:1133-6.
57. Greene Y, Tariot P, Wishart H, et al. A 12-week, open-label trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol 2000;20:350-6.